Literature DB >> 24890884

Kidney cancer: bisphosphonates in the era of antiangiogenic targeted therapy.

Frederik C Roos1.   

Abstract

Bone is the second most common metastatic site in patients presenting with metastatic renal cell carcinoma. Bisphosphonates have been approved to reduce bone pain and the risk of skeletal-related events (SREs) in such patients; however, new research suggests bisphosphonates do not improve survival or prevent development of SREs.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24890884     DOI： 10.1038/nrurol.2014.120

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  8 in total

1.  Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.

Authors:  Daniel Keizman; Maya Ish-Shalom; Roberto Pili; Hans Hammers; Mario A Eisenberger; Victoria Sinibaldi; Ben Boursi; Natalie Maimon; Maya Gottfried; Henry Hayat; Avivit Peer; Svetlana Kovel; Avishay Sella; Raanan Berger; Michael A Carducci
Journal:  Eur J Cancer       Date:  2012-03-10       Impact factor: 9.162

2.  Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).

Authors:  Manfred Wirth; Teuvo Tammela; Virgilio Cicalese; Francisco Gomez Veiga; Karl Delaere; Kurt Miller; Andrea Tubaro; Matthias Schulze; Frans Debruyne; Hartwig Huland; Anup Patel; Frederic Lecouvet; Christien Caris; Wim Witjes
Journal:  Eur Urol       Date:  2014-02-20       Impact factor: 20.096

3.  Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.

Authors:  Rana R McKay; Xun Lin; Julia J Perkins; Daniel Y C Heng; Ronit Simantov; Toni K Choueiri
Journal:  Eur Urol       Date:  2014-02-26       Impact factor: 20.096

Review 4.  Are bisphosphonates an indispensable tool in the era of targeted therapy for renal cell carcinoma and bone metastases?

Authors:  Daniel Keizman; Maya Ish-Shalom; Natalie Maimon; Maya Gottfried
Journal:  World J Urol       Date:  2013-03-31       Impact factor: 4.226

5.  Skeletal complications and survival in renal cancer patients with bone metastases.

Authors:  Emma Woodward; Satinder Jagdev; Lucy McParland; Katy Clark; Walter Gregory; Alex Newsham; Suzanne Rogerson; Kate Hayward; Peter Selby; Janet Brown
Journal:  Bone       Date:  2010-09-18       Impact factor: 4.398

6.  Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

Authors:  B Beuselinck; S Oudard; O Rixe; P Wolter; A Blesius; J Ayllon; R Elaidi; P Schöffski; E Barrascout; A Morel; B Escudier; H Lang; J Zucman-Rossi; J Medioni
Journal:  Ann Oncol       Date:  2010-10-11       Impact factor: 32.976

7.  Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.

Authors:  Allan Lipton; Ming Zheng; John Seaman
Journal:  Cancer       Date:  2003-09-01       Impact factor: 6.860

8.  Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases.

Authors:  F Saad; J E Brown; C Van Poznak; T Ibrahim; S M Stemmer; A T Stopeck; I J Diel; S Takahashi; N Shore; D H Henry; C H Barrios; T Facon; F Senecal; K Fizazi; L Zhou; A Daniels; P Carrière; R Dansey
Journal:  Ann Oncol       Date:  2011-10-10       Impact factor: 32.976
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.